5+ hour, 32+ min ago  (664+ words) The GLP-1 Mood Signal Is Real " But So Is the Psychiatric Worsening Risk'The Clinical Trial Vanguard The GLP-1 Mood Signal Is Real " But So Is the Psychiatric Worsening Risk A pattern I've been tracking across my dual-diagnosis patient panel this…...

5+ day, 14+ hour ago  (556+ words) Minerva Presents Safety Trial Data on Roluperidone, Olanzapine'The Clinical Trial Vanguard Minerva Presents Safety Trial Data on Roluperidone, Olanzapine Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects and no…...

4+ mon, 3+ week ago  (685+ words) Reviva will present new analyses on negative symptoms with brilaroxazine from its Phase 3 RECOVER double'blind trial in acutely exacerbated schizophrenia and from a one'year open'label extension in clinically stable patients at CNS Summit 2025 in Boston. The poster, "Brilaroxazine Treatment Effect…...

8+ mon, 3+ week ago  (385+ words) Salarius Pharmaceuticals announced positive preclinical data on its LSD1 inhibitor, seclidemstat, and provided an update on its merger with Decoy Therapeutics. Two recently published animal studies reinforce the potential of LSD1 inhibition in treating various cancers. Simultaneously, Salarius continues to progress toward…...